Loading…
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $8M | $-70M | $-65M | $-47M | -63.0% | -58.2% | - |
| 2024 | $19M | $-50M | $-132M | $-56M | -84.9% | -40.1% | - |
| 2023 | $31M | $-115M | $-88M | $-80M | -56.3% | 5.0% | - |
| 2022 | $30M | $-84M | $-87M | $-68M | -44.0% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 29.75 | 31.25 | 18.72 | 7.83 |
| Cost Of Revenue | 11.96 | 18.08 | 15.46 | 7.28 |
| Gross Profit | 17.79 | 13.17 | 3.26 | 0.54 |
| Operating Expense | 102.95 | 129.48 | 53.88 | 70.80 |
| Operating Income | -85.15 | -116.31 | -50.61 | -70.26 |
| EBITDA | -84.36 | -115.45 | -49.81 | -69.81 |
| EBIT | -85.15 | -116.31 | -50.61 | -70.26 |
| Pretax Income | -86.91 | -88.85 | -132.06 | -64.92 |
| Tax Provision | 0 | -0.37 | 0 | 0 |
| Net Income | -86.91 | -88.48 | -132.06 | -64.92 |
| Net Income Common Stockholders | -86.91 | -88.48 | -132.06 | -64.92 |
| Total Expenses | 114.91 | 147.56 | 69.33 | 78.09 |
| Interest Income | 0 | 0 | 7.95 | 7.64 |
| Research And Development | 77.81 | 98.38 | 33.59 | 52.65 |
| Selling General And Administration | 25.13 | 31.10 | 22.20 | 21.97 |
| Normalized EBITDA | -79.66 | -134.41 | 39.60 | -67.51 |
| Normalized Income | -82.21 | -107.36 | -42.66 | -62.62 |
| Basic EPS | -1.33 | -1.27 | -1.71 | 0 |
| Diluted EPS | -1.33 | -1.27 | -1.71 | 0 |
| Tax Effect Of Unusual Items | 0 | 0.08 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Total Unusual Items | -4.70 | 18.96 | -89.41 | -2.30 |
| Total Unusual Items Excluding Goodwill | -4.70 | 18.96 | -89.41 | -2.30 |
| Net Income From Continuing Operation Net Minority Interest | -86.91 | -88.48 | -132.06 | -64.92 |
| Reconciled Depreciation | 0.80 | 0.86 | 0.81 | 0.45 |
| Reconciled Cost Of Revenue | 11.96 | 18.08 | 15.46 | 7.28 |
| Net Interest Income | 0 | 0 | 7.95 | 7.64 |
| Net Income From Continuing And Discontinued Operation | -86.91 | -88.48 | -132.06 | -64.92 |
| Total Operating Income As Reported | -89.85 | -97.36 | -141.93 | -76.38 |
| Diluted Average Shares | 65.21 | 69.81 | 77.30 | 0 |
| Basic Average Shares | 65.21 | 69.81 | 77.30 | 0 |
| Diluted NI Availto Com Stockholders | -86.91 | -88.48 | -132.06 | -64.92 |
| Net Income Including Noncontrolling Interests | -86.91 | -88.48 | -132.06 | -64.92 |
| Net Income Discontinuous Operations | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | -86.91 | -88.48 | -132.06 | -64.92 |
| Other Income Expense | -1.75 | 27.47 | -89.41 | -2.30 |
| Other Non Operating Income Expenses | 2.95 | 8.51 | 7.95 | 0 |
| Special Income Charges | -4.70 | 18.96 | -89.41 | -2.30 |
| Other Special Charges | 0 | 6.63 | 86.91 | 0 |
| Write Off | 0 | 1.31 | 0 | 0 |
| Impairment Of Capital Assets | 0 | 6.63 | 0 | 0 |
| Restructuring And Mergern Acquisition | 4.70 | -26.90 | 2.50 | 2.30 |
| Net Non Operating Interest Income Expense | 0 | 0 | 7.95 | 7.64 |
| Interest Income Non Operating | 0 | 0 | 7.95 | 7.64 |
| Other Operating Expenses | 0 | 0 | -1.91 | -3.81 |
| General And Administrative Expense | 25.13 | 31.10 | 22.20 | 21.97 |
| Other Gand A | 8.96 | 10.80 | 8.63 | 7.05 |
| Salaries And Wages | 16.17 | 20.30 | 13.57 | 14.92 |
| Operating Revenue | 29.50 | 31.25 | 18.72 | 7.83 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Aclaris Therapeutics, Inc.this co. | ACRS | $624M | - | 5.23 | -63.0% | -6.08 |
| Bioventus Inc. | BVS | $654M | 29.30 | 3.52 | 10.0% | 12.31 |
| Eton Pharmaceuticals, Inc. | ETON | $645M | - | 24.38 | -17.6% | 73.07 |
| HealthStream, Inc. | HSTM | $641M | 34.05 | 1.76 | 5.2% | 9.46 |
| Prime Medicine, Inc. | PRME | $638M |
| - |
| 5.17 |
| -166.4% |
| -2.81 |
| Arvinas, Inc. | ARVN | $628M | - | 1.44 | -18.6% | 0.43 |
| CorMedix Inc. | CRMD | $591M | 3.67 | 1.46 | 40.2% | 3.38 |
| Prothena Corporation plc | PRTA | $585M | - | 2.09 | -87.0% | -1.56 |
| Anteris Technologies Global Corp. | AVR | $574M | - | -2950.00 | - | -6.11 |
| Peer Median | - | 29.30 | 1.93 | -17.6% | 1.91 | |